Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

Patients with COPD were randomly assigned to triple inhaled therapy with either a 160-μg or 320-μg dose of budesonide or to one of two dual therapies. Both triple regimens were superior to the dual regimens with respect to the rate of moderate or severe exacerbations; no difference was observed betw...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-07, Vol.383 (1), p.35-48
Hauptverfasser:	Rabe, Klaus F, Martinez, Fernando J, Ferguson, Gary T, Wang, Chen, Singh, Dave, Wedzicha, Jadwiga A, Trivedi, Roopa, St. Rose, Earl, Ballal, Shaila, McLaren, Julie, Darken, Patrick, Aurivillius, Magnus, Reisner, Colin, Dorinsky, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetylcholine receptors (muscarinic) Administration, Inhalation Adrenergic beta-2 Receptor Agonists - administration & dosage Adrenergic beta-2 Receptor Agonists - adverse effects Adult Aged Aged, 80 and over Asthma Budesonide Budesonide - administration & dosage Budesonide - adverse effects Chronic obstructive pulmonary disease Double-Blind Method Drug Combinations Female Forced Expiratory Volume - drug effects Formoterol Formoterol Fumarate - administration & dosage Formoterol Fumarate - adverse effects Glucocorticoids Glucocorticoids - administration & dosage Glucocorticoids - adverse effects Glycopyrrolate Glycopyrrolate - administration & dosage Glycopyrrolate - adverse effects Humans Inhalers Intention to Treat Analysis Kaplan-Meier Estimate Lung diseases Male Middle Aged Muscarinic Antagonists - administration & dosage Muscarinic Antagonists - adverse effects Obstructive lung disease Pneumonia Population Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - mortality Quality of life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with COPD were randomly assigned to triple inhaled therapy with either a 160-μg or 320-μg dose of budesonide or to one of two dual therapies. Both triple regimens were superior to the dual regimens with respect to the rate of moderate or severe exacerbations; no difference was observed between the triple regimens.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1916046